Garadacimab
Hereditary Angioedema
CSL Behringmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Hereditary Angioedema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Firazyr Nang Kuang Pharmaceutical Co., Ltd. | Phase 4 | A |
Firazyr Nang Kuang Pharmaceutical Co., Ltd. | Phase 4 | A |
Sebetralstat KalVista Pharmaceuticals, Ltd. | Phase 4 | A |
Berotralstat BioCryst Pharmaceuticals | Phase 3 | A |
Lanadelumab Takeda | Phase 3 | A |
View all 37 →
Same molecule, other indications
Garadacimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →